Skip to content

Robin K Dore MD, Inc.

Menu
  • Home
  • About the Practice
    • Office Directions
    • Insurance
    • Billing
    • Fragrance Free Policy
  • About Dr Dore
    • Publications
    • Professional Associations
  • Patient Information
    • Patient Forms
    • Patient Education
  • Clinical Research
    • Current Enrolling Studies
    • Do you have Rheumatoid Arthritis?
    • Do you have Psoriatic_Arthritis?
  • Bone Densitometry
  • Contact

Clinical Research

Clinical investigator, Dr. Dore participates as a Principal Investigator in clinical research studies of medications for treatment of gout, osteoarthritis, osteoporosis, rheumatoid arthritis, Lupus, metabolic bone and other auto-immune diseases. She has investigated multiple phase trials for over the last 30+ years.  Studied agents include, but not limited to: anti-TNF, anti-IL1, COX-2, RANK ligand inhibitor, selective estrogen receptor modulator, parathyroid hormone, Anti-Blyss antibodies, anti- IL-17, anti-IL-23 and other agents.

Please click here to find out about Current Enrolling Studies.

To CONTACT US:

Robin K. Dore, MD, Inc.
Clinical Research
12791 Newport Ave., Suite 201
Tustin, CA 92780

T.714.505.5500
F.714.505.3381
Email: research@robinkdoremd.com

Dr Dore’s studies are summarized below.

Ongoing and Past Clinical Research Study Collaborative Protocols Summary

2000-Current:

AbbVie (Abbott):

  • ABT-494 (JAK), multi center, randomized, treatment for RA: 2015→ongoing
  • adalimumab, multi center, randomized, treatment for RA, extension studies
  • adalimumab, multi center, randomized, treatment for Axial Spondyloarthritis

Amgen:

  • brodalumab, multi center, randomized, treatment for PsA
  • romosozumab, multi center, randomized, treatment for OP
  • denosumab multi center, randomized, treatment for OP
  • etanercept multi center, randomized, treatment for RA; open label extension study
  • anakinra, multi center, randomized, treatment for RA
  • etanercept, multi center, etanercept and MTX, mono/combo therapy, PsA; 2015→ongoing

AztraZenca:

  • fostamatinib disodium, multi center, randomized, treatment for RA

Bristol-Myers Squibb:

  • SQ abatacept, multi center, randomized, treatment for early RA

Biogen:

  • 2-Part, multi center, Eval safety and efficacy of sq BIIB059, SLE/CLE, 2016→ongoing

Eli Lilly & Co.:

  • ixekizumab, multi center, randomized, treatment for PsA: 2015→ongoing
  • arzoxifene, multi center, randomized, treatment for OP
  • teriparatide, multi center, randomized, tx for; OP, GIOP, device, observational
  • raloxifene, multi center, randomized, treatment for OP

GlaxoSmithKline:

  • GW406381 (cox-2) multi center, randomized, treatment for RA
  • belimumab, Auto-injector Device, multi center, SLE subjects

 HMR:

  • risedronate, multi center, randomized, treatment for OP; compliance

Human Genome Science/GSK:

  • belimumab, multi center, randomized, treatment for SLE

Knoll:

  • RA observational trial for RA meds

Merck:

  • alendronate, multi center, randomized, treatment for OP
  • rofecoxib, multi center, randomized, treatment for RA
  • zostavax, multi center, randomized, treatment for shingles vaccination

Novartis:

  • secukinumab, multi-center, safety/efficacy of secukinumab, PsA, 2016→ongoing

NPS Allelix:

  • PTH 1-84, multi center, randomized, treatment for OP

Optime:

  • liposome-encapsulated diclofenac analgesic (LEDA) multi center, randomized, treatment for OA knee

Oxford Outcomes:

  • Osteoporosis Questionnaire validation studies

Pfizer:

  • tofacitinib, 5mg multi center, randomized, treatment for RA; 2014→ongoing
  • tofacitinib, 11 mg XR multi center, randomized, treatment for RA; 2017→ongoing

Regeneron:

  • iL1, multi center, randomized, treatment for RA

Roche:  

  • ibandronate, multi center, randomized, treatment for OP
  • tocilizumab, multi center, randomized, treatment for RA; open label extension study

Sanofi Aventis:

  • sarilumab, multi center, randomized, treatment for Ankylosing Spondylitis
  • sarilumab, multi center, randomized, treatment for RA

Serono:

  • onercept, multi center, randomized, treatment for Psoriasis and Plaque Psoriasis

UCB:

  • certolizumab pegol, multi center, randomized, treatment for RA

Vertex: V

  • X-509 (JAK3) multi center, randomized, treatment for RA
Visit The Patient Portal

Schedule an appointment

To schedule an appointment or communicate with our office:

Telephone: (714) 505-5500
Fax: (714) 505-3381
Email: info@robinkdoremd.com

Read About Dr Dore's Fragrance Free Policy.

Also review Patient Forms prior to a visit.

HIPAA Privacy Notice

Useful Web References

Corona Virus Patient Support
(NEW) Watch Dr Dore talk about Fibromyalgia
Arthritis foundation
Lupus Foundation
National Osteoporosis Foundation
ASBMR
American College of Rheumatology
International Society for Clinical Densitometry

Robin K Dore MD, Inc. 2025 . Powered by WordPress